Compare Nuwellis Inc (NUWE) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Nasdaq100 ETF — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Nasdaq100 ETF trades at $751.29 (market cap $506.92B). The key difference: Nasdaq100 ETF is far larger — about 230418.2× Nuwellis Inc's market cap, and Nasdaq100 ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Nasdaq100 ETF for 162 Days on average.
| NUWE | QQQ | |
|---|---|---|
Market Cap | $2.20M | $506.92B |
Volume | 121,544 | 48,326,518 |
Sector | Health | — |
52-Week High | $146.65 | $759.66 |
52-Week Low | $0.68 | $558.34 |
Typical Hold Time | 26 Days | 162 Days |
Enterprise Value | -$1.52M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
QQQ trades at $750.47, down 0.96% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF faces mixed analyst sentiment with a 50/50 split between buy and sell recommendations. Recent news highlights QQQ's strong 10-year performance and ongoing innovation with new fund launches, though concerns about AI market valuations and interest rate impacts create headwinds.
The outlook remains cautiously optimistic given QQQ's tech-heavy exposure to AI growth trends, but elevated valuations and macroeconomic sensitivity present near-term risks. Long-term growth potential persists through innovation leadership, though investors should monitor concentration risk in technology holdings and market volatility around Fed policy decisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
